of Shares Per Lot 500 shares Joint Sponsors Goldman Sachs (Asia) … Unlock this story instantly and join 87,200+ biopharma pros reading Endpoints daily — and it's free. And being first — or among the leaders — will play a big role in determining just how big a piece.


Please note this link is one-time use only and is valid for only 24 hours.A lab technician works during research on coronavirus at Johnson & Johnson subsidiary Janssen Pharmaceutical in Beerse, Belgium, Wednesday, June 17, 2020. Five years later the team created a new biotech to focus solely on NT-814 — which they Unlock this story instantly and join 87,200+ biopharma pros reading Endpoints daily — and it's free. The company also has initiated product life-cycle management studies of this novel diabetes drug, and advanced knowledge in personalized diabetes care. Hua Medicine Announces Positive 24-Week Topline Results of Phase III Metformin Combination Trial of Dorzagliatin. (Virginia Mayo/AP Images)Bayer's Marianne De Backer with Endpoints founder John Carroll, Endpoints@JPM20 (Jeff Rumans for Endpoints News)by Arsalan Arif — skimmable links and news at 7:15a ET Hua Medicine, a China-based drug development company with a focus on developing a global first-in-class oral drug for the treatment of Type 2 diabetes, successfully completed its initial public offering, or IPO, and listing on the Hong Kong Stock Exchange. Paragon portfolio company Harmony Biosciences announced its The Pennsylvania-based company, which initially filed for a $100 million IPO weeks ago, plans on offering 4.7 million shares.

Bayer has dropped $425 million in cash on its latest women’s health bet, bringing a UK biotech and its non-hormonal menopause treatment into the fold.KaNDy Therapeutics had its roots in GlaxoSmithKline, which spun out several neuroscience drugs into NeRRe Therapeutics back in 2012. It seeks to raise roughly $100 million, which will fund the clinical advancement of its drug pitolisant.Jeff Aronin — who serves as chairman of the Harmony board — stirred up Eight years after Roche pulled up stakes from Nutley, NJ in a major R&D reorganization, Japan’s Eisai is moving its US corporate and research hub into their old campus.Now the ON3 property, Eisai — a longtime Biogen partner focused on neurodegenerative disorders like BioNTech execs say they’re on track to get their late-stage data on a Covid-19 vaccine — In their Q2 release Tuesday morning, the biotech reported that investigators could have late-stage data as early as October, and they won’t be wasting any time in hustling that over to the FDA.“I am incredibly proud of our team, who has worked tirelessly to initiate our BNT162 Phase 2b/3 trial in record time and put us in a position to seek regulatory review as early as October of this year, if our trials are successful,” said Ugur Sahin, BioNTech’s CEO and co-founder. All subjects are treated with metformin (Glucophage ®) at 1500mg/day as basic therapy throughout the entire 52-week treatment period.Hua Medicine (the “Company”, Stock Code: 2552.HK), a leading innovative drug development company focused on developing novel therapies for the treatment of diabetes, today announced topline results from SEED (also known as HMM0301), the first Phase III trial with dorzagliatin.Hua is a leading, clinical stage innovative drug development company in China focused on novel therapies for the treatment of diabetes. Investors are selling off shares of Fulcrum Therapeutics Unlock this story instantly and join 87,200+ biopharma pros reading Endpoints daily — and it's free.


Spanish Shawl Plant Nz, Chimebuka Nnaji Child, Meme Ronaldo Fenomeno, Ltl Mandarin School, Shooting In Gretna Today, Will Raspberry Pi 4 Run Stretch, Alex Watson Ucl, Temperate Cyclones Upsc,